Skip to main content
KISS is conducting a 2-minute survey to gather insights on the integration and usage of AI in business and marketing operations across different sectors including, Science, Technology, Education, Agriculture and Professional Services. We are looking to help identify industry trends, support needs, and guide innovation and anonymised results will be shared with all participants. Fill out the survey here. Questions we are asking include: What kind of training would be most beneficial for your organisation regarding AI and AI tools? What are your primary concerns or worries regarding the use of…
Continuous 2 is an active project aiming to address the growing demand for cost-effective biologics treatments. With the global biopharmaceutical market estimated to grow to 3.9bn by 2024, the industry must act quickly to make these life-changing drugs more accessible to patients, and respond to the demand for flexible manufacturing technology that delivers real-time release of biotherapeutics. UK Continuous 2 is building on the achievements of two previous projects: UK Integrated Continuous Bioprocessing project 2020: this project established an integrated continuous downstream manufacturing…
The July edition of our People Pathways newsletter is now available to read here. You can read about:✴ New and upcoming One Nucleus courses✴ Registration open for the next BLSA SIG webinar✴ Reflections and takeaways from our Neurodiversity webinar✴ New mentoring opportunitiesand more...
French biophysics pioneer Depixus has launched its inaugural Research Program, offering free access to the company’s unique single molecule interactomics technology. Depixus’ scalable magnetic force spectroscopy (MFS) platform is the first technology that allows researchers to simultaneously explore dynamic interactions between thousands of individual molecules in near real-time. The platform is able to analyze interactions between various combinations of RNA, DNA, proteins, and small molecules, providing unprecedented insights into mechanisms of action, binding kinetics and more. It is…
One Nucleus and Life Science Nation unite for the Genesis 2024 and Redefining Early Stage Investments (RESI) Conferences to Amplify Impact on Life Science Innovation. Boston MA and London UK, 31 July 2024 - One Nucleus and Life Science Nation (LSN) are pleased to announce the co-location of their renowned Genesis 2024 and Redefining Early Stage Investments (RESI) conferences, scheduled to take place on 4 December 2024, in London. The Genesis Conference programme will be at 1 Wimpole Street, and RESI will be at 11 Cavendish Square, allowing attendees to participate in either or both…
Metrion Biosciences' webinar ‘In Vitro Assessment of Cardiac Risk in Drug Discovery’ enabled attendees to learn how an hiPSC-CM model can help provide clear decision-making data for their project team, avoiding costly issues related to QTc and QRS cardiac liabilities in the clinic. Presentations were received from: Derek Leishman (VP Translational and Quantitative Toxicology at Eli Lilly and Company) presented the opportunities a sponsor now has available to increase the efficiency and effectiveness of QTc assessment by leveraging the ICH S7B core assays. He also discussed times when the…
Cushman & Wakefield has released its latest Life Sciences Lab Report on the UK's Golden Triangle. The Golden Triangle report looks closely at investment volumes, leasing take up, lab supply and pipeline, and investment into life sciences real estate across Cambridge, Oxford and London. Q2 2024 Take-Up Statistics • Golden Triangle leasing activity totalled 39,700 sq ft in Q2 2024. • This lull is typical for the second quarter, with 2024 likely to be the fourth year out of the past six where Q2 has reported the lowest quarterly volume of the year. • Under-offer space totalled 131,500…
Cambridge, UK, 23 July 2024: Metrion Biosciences Ltd (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Dr Chris Mathes, MBA, as Chief Commercial Officer (CCO). Chris will work alongside the Company’s expert leadership team to drive commercial strategy and lead global business development and marketing activities. Following completion of Metrion’s £3.7M equity financing in December 2023, the Company has made several high-profile appointments. Chris’ appointment as CCO further strengthens the…
Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets Cambridge, UK, 24 July 2024: Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer. An experienced global life sciences executive, Steve will guide the expansion of the Company’s commercial operations and implement a robust go-to-market strategy for its Next-Generation Sequencing (NGS)-based DNA…
Read the letter here